Squarepoint’s Larimar Therapeutics LRMR Stock Holding History

Squarepoint’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-40,000	Closed	-$304K	–	4405
2024 Q1	$304K	Buy	+40,000	New	+$312K	﹤0.01%	3373

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Squarepoint's LRMR Position: Q1 2026 in Review

Squarepoint sold out of Larimar Therapeutics (LRMR) in Q1 2026, closing a stake of 30,416 shares — an estimated $116K sold.

Squarepoint first reported a position in LRMR in Q4 2015 and held it in 17 quarters. The position peaked at $551K in Q3 2018. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

Squarepoint reported no remaining Larimar Therapeutics position as of Q1 2026 after selling out during the quarter.
Squarepoint sold 30,416 Larimar Therapeutics shares in Q1 2026, an estimated $116K.
Squarepoint first reported a position in Larimar Therapeutics in Q4 2015 and held it in 17 quarters.
Squarepoint's Larimar Therapeutics position peaked at $551K in Q3 2018.
162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.